PATENT CLAIM ANALYSIS

Application Number: 16228682
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "100000"]

Abstract:
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 1):
A high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein ibrutinib is a compound with the structure of Compound 1, and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.51923
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15970721', '15060010', '15909779', '15462444', '14821290']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7248356101014882
- 35 USC 102 Novelty (BERT): 0.513740704978332
- Combined Prediction Score: 0.7037261195891725
- Mean Citation Score: 296.1676700000001
- Max Citation Score: 313.1944299999999
- Similarity Product: 256.02434826947325

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test